These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 36107519)
21. Circulating melanoma cells as a potential biomarker to detect metastasis and evaluate prognosis. Hida T; Yoneta A; Wakamatsu K; Yanagisawa K; Ishii-Osai Y; Kan Y; Kato J; Yamashita T Australas J Dermatol; 2016 May; 57(2):145-9. PubMed ID: 26931184 [TBL] [Abstract][Full Text] [Related]
22. Serum levels of sICAM-1 and 5-S-cysteinyldopa as markers of melanoma progression. Hirai S; Kageshita T; Kimura T; Tsujisaki M; Imai K; Wakamatsu K; Ito S; Ono T Melanoma Res; 1997 Feb; 7(1):58-62. PubMed ID: 9067966 [TBL] [Abstract][Full Text] [Related]
23. Usefulness of serum 5-S-cysteinyl-dopa as a biomarker for predicting prognosis and detecting relapse in patients with advanced stage malignant melanoma. Umemura H; Yamasaki O; Kaji T; Otsuka M; Asagoe K; Takata M; Iwatsuki K J Dermatol; 2017 Apr; 44(4):449-454. PubMed ID: 27786364 [TBL] [Abstract][Full Text] [Related]
24. Use of serum 5-S-CD and S-100B protein levels to monitor the clinical course of malignant melanoma. Bánfalvi T; Gilde K; Gergye M; Boldizsár M; Kremmer T; Ottó S Eur J Cancer; 2003 Jan; 39(2):164-9. PubMed ID: 12509947 [TBL] [Abstract][Full Text] [Related]
25. [Laboratory markers of melanoma progression]. Bánfalvi T; Edesné MB; Gergye M; Udvarhelyi N; Orosz Z; Gilde K; Kremmer T; Ottó S; Tímár J Magy Onkol; 2003; 47(1):89-104. PubMed ID: 12704461 [TBL] [Abstract][Full Text] [Related]
26. Evaluation of the clinical usefulness of measuring urinary excretion of 5-S-cysteinyldopa in melanoma: ten years' experience of 50 patients. Sasaki Y; Shimizu H; Naka W; Takeshita E; Nishikawa T Acta Derm Venereol; 1997 Sep; 77(5):379-81. PubMed ID: 9298132 [TBL] [Abstract][Full Text] [Related]
27. Treatment of primary melanoma of the lung monitored by 5-S-cysteinyldopa levels. Shikuma K; Omasa M; Yutaka Y; Okuda M; Taki T Ann Thorac Surg; 2009 Apr; 87(4):1264-6. PubMed ID: 19324166 [TBL] [Abstract][Full Text] [Related]
28. 5-S-cysteinyldopa as diagnostic tumor marker for uveal malignant melanoma. Goto H; Usui M; Wakamatsu K; Ito S Jpn J Ophthalmol; 2001; 45(5):538-42. PubMed ID: 11583680 [TBL] [Abstract][Full Text] [Related]
29. [5-S-cysteinyldopa in the urine - a "tumor test" for malignant melanoma? Comparison with the usual laboratory examinations]. Paul E; Graef V; Ruppel R Z Hautkr; 1980 Dec; 55(23):1543-60. PubMed ID: 6782780 [TBL] [Abstract][Full Text] [Related]
30. Studies on amelanotic melanoma with the fluorescence method (Falck and Hillarp) and biochemical analysis of 5-S-cysteinyldopa in the tissues. Morishima T; Tatsumi F; Fukada E; Watanabe M; Nagashima N; Hanawa S Arch Dermatol Res; 1983; 275(5):329-33. PubMed ID: 6419680 [TBL] [Abstract][Full Text] [Related]
31. [Excretion of 5-S-cysteinyldopa in the urine of Japanese patients with malignant melanoma--a helpful biochemical marker for assessing the progression of disease]. Hanawa S Nihon Hifuka Gakkai Zasshi; 1983 Mar; 93(4):433-42. PubMed ID: 6411952 [No Abstract] [Full Text] [Related]
32. [Biochemical diagnoses of malignant melanomas with determinations of 5-S-cysteinyldopa in lesions]. Sameshima T; Morishima T Nihon Hifuka Gakkai Zasshi; 1989 May; 99(6):665-72. PubMed ID: 2511358 [TBL] [Abstract][Full Text] [Related]
33. Measurement of eumelanin precursor metabolites in the urine as a new marker for melanoma metastases. Yamada K; Walsh N; Hara H; Jimbow K; Chen H; Ito S Arch Dermatol; 1992 Apr; 128(4):491-4. PubMed ID: 1580656 [TBL] [Abstract][Full Text] [Related]
34. Urinary excretion of 5-S-cysteinyldopa in patients with primary melanoma or melanoma metastasis. Agrup G; Agrup P; Andersson T; Falck B; Hansson J-A ; Jacobsson S; Rorsman H; Rosengrem A-M ; Rosengren E Acta Derm Venereol; 1975; 55(5):337-41. PubMed ID: 52967 [TBL] [Abstract][Full Text] [Related]
35. Determination of 5-S-cysteinyldopa in plasma and urine using a fully automated solid-phase extraction--high-performance liquid chromatographic method for an improvement of specificity and sensitivity of this prognostic marker of malignant melanoma. Hartleb J; Damm Y; Arndt R; Christophers E; Stockfleth E J Chromatogr B Biomed Sci Appl; 1999 Apr; 727(1-2):31-42. PubMed ID: 10360420 [TBL] [Abstract][Full Text] [Related]
36. Seasonal variation in serum concentration of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid in healthy Japanese. Wakamatsu K; Ito S Pigment Cell Res; 1995 Jun; 8(3):132-4. PubMed ID: 7567788 [TBL] [Abstract][Full Text] [Related]
37. The value of cysteinyldopa in the follow-up of disseminated malignant melanoma. Kärnell R; Kågedal B; Lindholm C; Nilsson B; Arstrand K; Ringborg U Melanoma Res; 2000 Aug; 10(4):363-9. PubMed ID: 10985671 [TBL] [Abstract][Full Text] [Related]
38. Plasma 5-S-cysteinyldopa differentiates patients with primary and metastatic melanoma from patients with dysplastic nevus syndrome and normal subjects. Peterson LL; Woodward WR; Fletcher WS; Palmquist M; Tucker MA; Ilias A J Am Acad Dermatol; 1988 Sep; 19(3):509-15. PubMed ID: 3139723 [TBL] [Abstract][Full Text] [Related]
39. [5-S-cysteinyldopa determination in the urine. Its value for monitoring in melanoma patients]. Paul E; Graef V; Ruppel R; Hellwich M Z Hautkr; 1983 Feb; 58(4):262-5. PubMed ID: 6405551 [TBL] [Abstract][Full Text] [Related]
40. Pedunculated pigmented eccrine poroma of the scalp with increased urinary excretion of 5-S-cysteinyldopa. Jin KM; Nogita T; Toyoda H; Kawashima M; Hidano A J Dermatol; 1990 Sep; 17(9):555-8. PubMed ID: 2177483 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]